Home / Transcripts / Cytek Biosciences, Inc. (CTKB) · November 5, 2025

Cytek Biosciences, Inc. (CTKB) Earnings Call Transcript

November 5, 2025

NASDAQ US Health Care Life Sciences Tools and Services earnings 45 min

Earnings Call Speaker Segments

Paul Goodson executive
#1

Thanks, operator. Today, Cytek Biosciences announced its financial results for Q3, which closed on September 30, 2025. Should you not have gotten that news release, or if you want to be put on the company's distribution list, just email investors@cytekbio.com. That news release can also be found in the Investor Relations portion of Cytek's site, at investors.cytekbio.com. Here with me from Cytek today are Wenbin Jiang, our CEO, and Bill McCombe, our CFO. I'd like to note that during today's call we'll refer to a slide presentation, which has been posted in the Investors section of our corporate website. Before we get started, I want to note that this call will contain forward-looking statements as defined under federal securities laws. These include remarks regarding Cytek's business plans, strategies, opportunities, and financial projections. Such statements are based on what the company currently expects and carry inherent significant risks and uncertainties, which could lead actual results or events to differ materially from what these statements anticipate. You can find additional details about these risks and uncertainties in our slide presentation, under the Forward-Looking Statements section of the press release Cytek released today, and in Cytek's SEC filings. Additionally, today's call will cover certain financial measures that are not prepared in accordance with generally accepted accounting principles. Details regarding our non-GAAP financial metrics, along with reconciliations to the closest comparable GAAP measures, are available in our slide deck and in the press release issued today. Although the company thinks these non-GAAP financial measures offer helpful information to investors, they should not be viewed by themselves or used in place of the financial information reported under GAAP. Unless the law requires otherwise, Cytek assumes no obligation to revise any forward-looking statements, whether as a result of fresh information, upcoming events, or shifts in its expectations. The content of this conference call is time-sensitive and holds true only as of the live broadcast on November 5, 2025. I'd like to express my appreciation to everyone who came to our User Group Meeting in New York City on October 22. Only 2 days remain until our next gathering, which will also be the final User Group Meeting of 2025, taking place November 7 in Montreal. Beyond these events, Cytek participates in many conferences across the industry around the globe, frequently setting up a booth so that those attending can view our products and gain knowledge about them from our well-informed team members. These events, as they always have been, are mainly intended for the scientific community, yet they can also create a chance for investors and analysts to engage with people who use our technologies and to discover the reasons our customers place such high value on Cytek's instruments. Since only a certain number of spots exist for people in the financial community, anyone hoping to join any of these events should reach out to me in January, at which point we'll have a roster of 2026 events ready. Having said that, I'll now hand things over to Wenbin.

Wenbin Jiang executive
#2

Thanks, Paul. Hi, everyone — I'm glad you're joining us to hear about Cytek. On today's call, I want to start with a look at our third-quarter results. Then I'll walk through a few of the advances we achieved on our strategic priorities during that quarter, and afterward Bill will take over to give you a closer review of the financials and what we expect going forward. Let's turn to Slide 3. For the third quarter of 2025, we recorded total revenue of $52.3 million, up 2% compared with the same quarter in 2024. That improvement was driven largely by robust double-digit expansion in Asia Pacific, as well as ongoing strength in our recurring revenue lines — particularly service and reagents. Now on Slide 4. Looking at things by region, APAC — China included — turned in our strongest results, with solid top-line gains everywhere from instruments to reagents to service. Stateside, total revenue climbed by a double-digit percentage versus a year earlier, powered by ongoing strength in service revenue. EMEA, on the other hand, posted a year-over-year top-line drop in the double digits, mostly because instrument sales to academic and government accounts fell sharply, while instrument sales to pharma, biotech and CRO clients slipped modestly. In our Rest of World territory, covering Canada and Latin America, total revenue rose by a double-digit rate against the third quarter of last year. On to Slide 5. One thing worth highlighting: aside from how EMEA performed, Cytek achieved revenue growth in the double digits across every region globally during Q3, which this slide illustrates. Turning to instruments now. Revenue from instruments sold to pharma and biotech clients rose 12% globally, with a 10% increase in the U.S., partly fueled by the rollout of our Aurora Evo instruments. In APAC, China included, instrument revenue climbed 20% versus the prior-year period, and it was up 32% year-over-year in the rest of the world. A favorable funding climate for academic institutions in those areas is propelling this strong momentum. Within the U.S., instrument revenue overall came in flat relative to the same period last year. U.S. On the instrument side, sales got a lift as pharma, biotech, and CRO customers stepped up their buying, something we attribute to clearer visibility into macro and industry conditions. Still, those gains were canceled out by ongoing weakness across academia and government, where money remained tied up amid shifting U.S. policy. During the quarter, that end market started showing signs of settling down. Even so, pressure on academic and government demand didn't let up, so U.S. instrument revenue came in flat year over year for Q3; in EMEA, instrument sales fell, with academia and government hit hardest, which we read as part of a wider reordering of public spending priorities. Turning to where our repeat business comes from, services kept expanding at a healthy clip and made a solid contribution to that recurring pool overall. Broad-based momentum was especially evident across APAC, spanning both services and reagents. Underpinning the service gains were a larger placed fleet of instruments along with heavy usage of what we sell. Reagent sales globally rose 21% versus the comparable stretch a year earlier, helped by operational improvements like faster turnaround and enhanced support for customers. Next, let me take you through the progress our team has made on the key strategic pillars — instruments, applications, bioinformatics and clinical — each meant to reinforce Cytek's position as a frontrunner in the next-gen cell analysis space. We'll start with our foundational instruments on Slide 6. In the third quarter, Cytek's global footprint grew by 161 instruments, bringing the cumulative installed base to 3,456 units. Within the product portfolio, the Aurora cell sorter stood out as the strongest performer in Q3, posting a 35% gain compared with the same period a year earlier. This expansion strikes us as especially significant, since competing platforms have recently appeared on the market. We introduced the Aurora Evo Analyzer toward the close of Q2, and the response has been encouraging. The Aurora Evo system reflects Cytek's commitment to remaining at the forefront of technological innovation in flow cytometry. It combines a unique blend of high throughput, top-tier data quality, small particle detection, user-friendly operation, along with automation and harmonization features. We anticipate it will become the benchmark others are compared against. These new capabilities came from heeding our customers' requests. And given how well Q3 went, it's evident that customers are gaining value from the additions we made in creating the Aurora Evo. Last, on instruments, I'd like to note that our Muse Micro Analyzer has seen a very positive reception since its debut this past March. The Muse Micro provides advanced microcapillary fluids, improved optics, superior software and wider assay compatibility, while still keeping costs low and the design compact; it's a great fit for researchers and labs looking for affordable flow cytometry systems. Now to our next growth pillar, applications, which covers reagents. Our focus remains on driving expansion within the reagent side of our product engine. In support of that, we recently announced that our European headquarters is getting bigger at the Amsterdam Life Science District site; that facility increases our EMEA presence by more than 40%, and a center devoted to customer service and training is part of it. We also relocated reagent warehouse activities to this location to advance the reagent business even more, which improves how nimbly and efficiently we operate, shortens the time it takes to turn things around, and gives customers reliable, uniform experiences. Over time, we expect the portion of revenue that recurs to continue growing. Now let's turn to bioinformatics. Cytek Cloud, as we have mentioned before, continues to bring substantial benefits to those who use it. Customers are able to streamline how they run experiments thanks to our software offerings, and that drives both uptake and greater use of our cell analysis products, while also lifting results in the reagent and service segments. By September 30, 2025, Cytek Cloud had amassed more than 22,600 users — a gain of over 40% from where we stood at the beginning of 2025, which averages out to roughly 8 users for each installed Cytek FSP instrument. In our view, this kind of growth reflects how committed our customer base is to the portfolio we bring to market, as well as the spillover benefit that Cytek Cloud delivers by increasing engagement with our technology platform — and that includes the recurring revenue streams from reagents and service. Just to remind everyone, Cytek Cloud is changing the way scientists plan and carry out complicated flow cytometry work. At the heart of it sits our Panel Builder, powered by our own AI, which spares people weeks or months by handling key steps automatically, such as choosing fluorochromes and matching markers. After that, researchers can run virtual studies prior to locking in actual wet lab work, which cuts down on trial and error and lifts data quality right from the beginning. Turning to clinical: we still see the clinical market as an appealing commercial opportunity for Cytek. During Q3, Cytek stepped into the spotlight to display our full cell analysis offerings at a number of industry conferences. A standout was the ESCCA gathering held in Montpellier, France, in September. Independent researchers gave presentations there about why special flow cytometry matters when carrying out in vitro diagnostic procedures, and they recognized that the Northern Lights-CLC system from Cytek is the sole special analyzer cleared for clinical use in the EU. Having said that, I'll hand the call to Bill now so he can share further specifics on our financials.

Bill McCombe executive
#3

Thank you, Wenbin. Now moving to Slide 7 to discuss our financial performance for the third quarter. We brought in total revenue of $52.3 million for Q3, which represents a 2% gain compared to Q3 of 2024. This improvement is due to robust expansion in service and reagents across the globe, along with instruments in Asia Pacific and a leveling off of U.S. instrument revenues. These gains were partially canceled out by ongoing softness in EMEA instrument revenues. We experienced 14% growth in overall revenues from biopharma customers worldwide compared to the same quarter last year, which was offset by a comparable drop in revenues from government and academic customers. Product revenue, consisting of instruments and reagents, fell 4% compared to Q3 of 2024, caused by a 26% decrease in EMEA that was offset by 19% expansion in APAC. U.S. product revenue rose 20% compared to Q2, yet remained flat compared to Q3 of 2024, which stood as the strongest quarter for product revenue in 2024. Our results in the U.S. stemmed from a 10% rise in instrument revenue from pharma and biotech customers, fueled by the introduction of our new Aurora Evo instrument and a better industry environment; this was offset by a 13% drop in instrument sales to academic and government customers as funding pressures persisted. Looking at EMEA, product revenue fell largely because academic and government customers brought in notably less money — something we tie to changed priorities in government spending — and pharma, biotech and CRO accounts also saw a decline in the single digits. Our reagent revenue is still only a single-digit percentage of total revenue, yet in Q3 it hit the highest quarterly figure we've ever recorded, growing 21% compared with the same quarter a year earlier. That result, as Wenbin mentioned, came mainly from our reagents team working hard to cut delivery times and step up customer service. Service kept up its strong revenue growth too, posting 19% growth in Q3 against the prior year quarter. The installed base expanded and people used our systems more actively, which fueled this. Let's move on to how we performed across geographic markets. Compared with the same period a year earlier, U.S. revenue rose 12% during Q3, with service revenue growth powering that gain. EMEA came in 28% lower, the result of weaker instrument revenue. APAC, China included, posted a 25% Q3 increase, lifted by gains in instruments, service and reagents. On a GAAP basis, gross profit reached $27.6 million, down 5% from Q3 of 2024. GAAP gross profit margin landed at 53%, compared with 56% in the equivalent quarter last year. The decline stemmed from two factors: service gross margin fell because we added staff and spent more on travel, while product gross margin dropped due to weaker product revenues, rising materials and tariff expenses, and greater overhead. On a GAAP basis, gross margin rose compared with Q2's 52%, driven by stronger product gross margins on higher product revenues and better overhead absorption. Adjusted gross profit margin—leaving out stock-based compensation and amortization of acquisition-related intangibles—reached 55% in Q3, versus 60% a year earlier and 56% in Q2. Operating expenses for the third quarter totaled $36.7 million, up $3.5 million, or 10%, from Q3 2024. This increase was driven by higher general and administrative costs, which were partially offset by decreases in R&D and in sales and marketing spending. R&D expenses came to $9 million, down 9% versus the same quarter a year earlier, primarily due to a smaller workforce and reduced compensation costs, with higher engineering expenses providing some offset. Sales and marketing expenses were $11.7 million, 6% lower than the year ago quarter, reflecting fewer employees and lower compensation costs as well as decreased outside services expenses. General and administrative expenses totaled $16.1 million, an increase of $5.2 million, or 47%, compared with the year ago quarter. That rise came mostly from expenses related to a patent lawsuit, plus a smaller item: a $0.7 million write-off of deferred offering costs that was non-recurring and non-cash, connected to an at-the-market equity financing facility we set up in 2022 that ran out this quarter. For Q3, our loss from operations reached $9.2 million, up against $4.2 million during the same period a year earlier. The drivers there were a GAAP gross profit decline of $1.5 million alongside a $3.5 million rise in operating expenses. Q3 brought a net loss of $5.5 million, whereas the prior year quarter delivered net income of $0.9 million; three things caused that swing. The first was a $5 million larger loss from operations, which I just described. Additionally, our net other income declined $3 million, landing at $1.4 million, whereas it had been $4.4 million during the same quarter a year earlier. The primary driver was $0.9 million in FX losses this quarter, contrasting with $1.1 million in FX gains during last year's comparable quarter, along with a $0.9 million drop in interest income. A bigger operating loss combined with the decrease in net other income — $8 million in total — was counterbalanced by a larger tax benefit of $2.3 million this quarter, which arose from a higher effective tax rate, versus a $0.8 million tax benefit in the year-ago quarter. On an adjusted EBITDA basis — leaving out stock-based compensation, foreign exchange effects, and that $0.7 million nonrecurring charge tied to writing off deferred offering costs — the figure dropped to $2.5 million, down from $7.6 million during the same quarter last year. The reasons were a $1.5 million decline in gross profits alongside $3.5 million more in operating expenses, driven by the factors I already walked through. Free cash flow came in just below zero, at negative $0.3 million for the quarter, which brought our combined cash and marketable securities down slightly, to $261.7 million. Now let's move to Slide 8 and discuss guidance for the full year. Our revenue outlook for full year 2025 stays the same, a range of $196 million to $205 million, and that assumes currency exchange rates hold steady. We're taking into account what we've achieved so far this year, the instrument sales prospects we have lined up for Q4, and the positive traction in both our service and reagent operations. Looking at this quarter, we saw instruments keep climbing sharply across APAC, the U.S. instruments picture level out, and our recurring revenue lines expand at a healthy pace. We expect those trends to persist, and our forecast matches the guidance we gave in previous quarters — namely that conditions would improve step by step as the year progressed. That is exactly what has been happening in the U.S. market, even as EMEA continues to struggle. It's worth stressing that we still think our results in Q3 and in 2025 year-to-date point to a robust leadership position in the marketplace amid what has been a tough environment. Outside of EMEA, every region is posting positive growth in our core business, and recurring revenue keeps expanding. Even with operating expenses that were temporarily higher than usual, we produced positive adjusted EBITDA, and we expect that to carry into Q4. Compared with the broader flow cytometry market, which is likewise starting to stabilize, we think we'll do well. And lastly, because our balance sheet is strong, we can keep putting money into growth. With that said, I'll hand things back to Wenbin.

Wenbin Jiang executive
#4

Appreciate it, Bill. Now moving to Slide 9. To wrap things up, I'd like to start by expressing gratitude to the entire Cytek team for the way they keep pushing our mission forward even as the market stays difficult and keeps shifting. In our view, the results for the third quarter are encouraging — they show what our established brands and solid technology can do, and they highlight where we stand as a market leader. Our people keep carrying out their work with discipline, broadening the installed base around the world, building up recurring revenue streams, and honing their attention on profitability along with cash generation. That said, we are dedicated to putting targeted investments to work that will strengthen how we compete and speed up our growth. Even though we stay aware of the wider market landscape, we think Cytek is positioned well to create long-term value via our distinctive technology portfolio, lasting growth drivers, a robust balance sheet, and worldwide reach. Thank you all for being on today's call, and at this point we'll take questions. Operator?

David Westenberg analyst
#5

To kick things off, I'd like to focus on that new offering, the Aurora Evo. Could you walk us through what sets it apart from competing items available today, and also share your perspective on how much of our growth over the coming 2 years will come from freshly introduced products?

Wenbin Jiang executive
#6

Regarding this launch, the key thing is that we paid close attention to what our buyers told us, particularly those in pharma biotech. As for capabilities, we built in greater throughput along with the ability to detect small particles, plus automation and harmonization — every one of those elements is genuinely tailored to the needs of those pharma clients.

David Westenberg analyst
#7

Understood. Now, regarding pharma clients — actually, what I meant to ask is whether the double-digit increase among CROs tells us anything. In other words, could those firms be early signals that biopharma companies will eventually choose to purchase their own equipment?

Bill McCombe executive
#8

When we discuss biopharma alongside CROs, we treat them as a single category. Thus, whenever Wenbin refers to biopharma customers, all of them are lumped together. As we mentioned during the remarks, instrument revenue from that group rose 12% globally and 10% within the U.S.; the feedback we've gotten has therefore been quite positive.

David Westenberg analyst
#9

Let me try putting the question a different way. The press release brought up CROs. From what I recall, it stated growth of 14%. Usually, when I consider CROs and how they're used...

Bill McCombe executive
#10

Right. What we were pointing to is that combined set of customers, made up of pharma companies, biotechs, CROs, and distributors. Those form a single customer group. So yes, per the press release, revenues overall from that combined set climbed 14% during the quarter. And as I noted a moment ago, for that very same set, instrument revenue was up 12%. The large pharmaceutical firms likely represent the biggest piece — the largest subcomponent — within that set. That's how you should think about it.

David Westenberg analyst
#11

Regarding that U.S. revenue growth in the double digits — could you help us understand how much of it comes from, hate to put it this way, softer year-ago comparisons rather than simply solid performance? And in your view, are we sitting at this point in the later stages of a — or maybe I should say the opening stages of a rebound rather than the closing stages of a slump; and I'll follow up with you separately after this.

Bill McCombe executive
#12

My take is — no, that isn't the case — last year's third quarter was quite robust. So the U.S. results reflect robust expansion in service and reagent, along with the fact that our instrument business in the U.S. was unchanged. But like I said during my prepared comments, for U.S. instruments, Q3 of last year stood as the top quarter of 2024. So the bar was in fact quite elevated. And so holding flat relative to that represents a fairly solid accomplishment. On the — what I'm referring to is — that's a fairly solid accomplishment when it comes to instruments. And beyond that, we saw robust expansion in services and reagents. Does that address what you were asking?

Brendan Smith analyst
#13

Thanks for all that detail. I was hoping to dig a bit deeper into how your discussions with customers have been going over the past few weeks. Is there anything more you can share regarding their willingness to increase spending on some of these instruments in the coming year, especially now that they're actively working on their 2026 budgets? And if that's the case, do you have a sense of which of your products they might turn to first once those funds become a bit more accessible next year? Also, I'm curious whether you're seeing any regional variations in your response to that.

Bill McCombe executive
#14

Yes. The patterns we're seeing right now in the business show that Asia Pac is performing well and expanding at a solid pace — the instrument business in Asia Pac is growing robustly. Momentum in service remains solid, and so does reagent. As we mentioned, EMEA is still facing difficulties. Meanwhile, the U.S. is tracking along the path we anticipated — one we discussed in prior quarters involving steady gains over the course of the year. And that's what we've observed. So we've seen the U.S. instrument business level out, essentially matching last year's performance for 2 consecutive quarters now. Obviously, we can't predict the future; but assuming nothing unexpected happens, we believe those patterns will persist. In the U.S., the biopharma segment, as we pointed out, has been — among U.S. instruments, biopharma has performed well. Academia and government have struggled, though the 2 have balanced each other out. So it's still a bit early for us to discuss 2026. The one thing we'd say is that we typically anticipate the parts of the business that are expanding will keep expanding, barring unforeseen events. And I believe eventually Europe has to reach its lowest point. It dropped considerably this year. You'll note it's down nearly 30% this year on a total revenue basis. And you'd expect that pace of decrease must decelerate.

Harrison Parsons analyst
#15

Harrison Parsons here, filling in for Mason. Could you take us through the main assumptions underpinning the 2025 outlook? Given the macro backdrop, are you factoring in the usual fourth-quarter step-up in instrument placements, or something softer?

Bill McCombe executive
#16

We'd — we see no reason — let me start over. From biopharma customers, we generally get a budget flush in Q4. We see no reason to question that it will occur — or to anticipate that it won't happen this year; thus, we'd anticipate some standard seasonal pickup in Q4. And again, I'd return to what I just noted regarding the outlook: momentum in service and reagents is strong. Asia Pac is strong. The U.S. is stable, and we believe EMEA will stay under pressure compared with last year.

Harrison Parsons analyst
#17

Got it. Next, I was hoping to dig a bit deeper on the U.S. What's the trend looked like for U.S. academic and government demand going back to last August? And heading into next year, is there anything suggesting it might be stabilizing?

Bill McCombe executive
#18

Compared with last year, it's still lower. And clearly, when it comes to the pressure on funding, or the cuts to funding, that situation hasn't shifted much. That said — on the other hand, as we mentioned, biopharma momentum has been pretty solid, pretty robust. So as far as U.S. academic and government goes, we see no basis to think things will become notably better or notably worse; our view is simply that it will stay under pressure relative to where it stood last year.

Harrison Parsons analyst
#19

All right. Then, I understand reagents are expanding, and you mentioned an annual opportunity above $150 million with under 10% currently captured. Which particular programs are you putting in place to raise that capture rate? And are you starting to observe results from those programs?

Wenbin Jiang executive
#20

As you're able to see, our operational efficiency and logistics functions have genuinely gotten better, and we cut delivery time substantially. Reagent, as everyone knows, is a recurring business, so all of those logistics-related problems must be tackled, and that is what our attention has been on for the past few quarters. And obviously, it has paid off — those sorts of enhancements we've implemented have delivered gains for us. Also, not long ago, we grew our European sites in Amsterdam and brought the reagent warehouse in-house, and clearly — and we expect to keep seeing the types of advantages we've achieved up to now.

Bill McCombe executive
#21

Another thing we're paying attention to is what we've talked about before regarding our design-in efforts, where we build a panel for a customer and leverage that to move more of our reagents. That's one more initiative.

Wenbin Jiang executive
#22

Cytek Cloud is another area we have leveraged to help drive our reagent business.

Bill McCombe executive
#23

Right. And last, we keep putting money into R&D to grow our reagent lineup. For some customers, we create bespoke reagents, and those could later be added to our catalog. That gives us one more route to grow the reagent side, one more effort. So we've got several irons in the fire across many areas.

Noah Lewis analyst
#24

This is Noah filling in for Andrew. To start, following up on that other question about the Q4 guidance and the full-year outlook, we had anticipated somewhat of a seasonal increase, yet you brought up budget flush. How much does the Q4 guide and the remainder of the year depend on an increase, or really a budget flush, as opposed to pure seasonality? Just attempting to gauge how the two split in terms of that increase.

Bill McCombe executive
#25

Those 2 terms, as we use them, essentially point to the same phenomenon. The seasonality we observe comes from customers using up whatever budget remains, or flushing it, so to speak. So really — those 2 phrases describe one and the same phenomenon. And like we said, we don't see that pretty typically each year. That happened last year; and it has happened regularly in earlier years. And as we've said, we have no information indicating that it wouldn't happen to some degree this year; therefore the outlook rests on, as we said, clearly, our results so far this year, the momentum in our recurring revenue businesses. So the growth drivers there are the reagent business we discussed, the installed base for services. After that we consider our pipeline of opportunities in the instrument business, and we incorporate all of those. And on that basis, we are reiterating our range.

Noah Lewis analyst
#26

All right. Understood. Yeah, I was just hoping to pin down if, by budget flush, you were saying the market had gotten notably better, though I get the seasonality part…

Bill McCombe executive
#27

Yeah. No, <<inaudible>> biopharma firms in particular set their budgets around a calendar year. That means once Q4 arrives, there's a bit of an incentive for them to use up whatever portion is left unspent, so that the entire budget gets used.

Noah Lewis analyst
#28

Understood. Perhaps one final thing. Alright, yes, apologies. Right, I meant to say my final point concerned deployment of capital. You mentioned having quite a robust balance sheet, plus you anticipate being free cash flow positive. So is there any desire for additional buybacks, and perhaps what are you observing regarding the acquisition pipeline — any interest on that front?

Bill McCombe executive
#29

Yeah, so the brief response is that our goal is to pursue both repurchasing shares and M&A. Regarding sizing our buybacks, what we've historically done is set them at roughly the same level as free cash flow. During the current year to date, we've in fact outspent our free cash flow when it comes to repurchasing shares. Consequently, since we exceeded free cash flow, no shares were purchased by us during the third quarter. Broadly though, our aim is to purchase — our strategy for buybacks involves being opportunistic and purchasing when conditions strike us as especially advantageous, while keeping those buybacks sized at somewhere generally within the bounds of our free cash flow. Thus, no adjustments are being made by us to that overall strategy, and we'll carry it out as opportunities arise down the line; next, concerning M&A, we keep evaluating a variety of potential deals. However, as you're aware, M&A chances are sporadic, arriving and departing in what could be called an inconsistent manner. Still, we are observing items. We are evaluating items, and growing via both organic and inorganic routes remains our goal.

Operator operator
#30

Alright, that brings our question-and-answer portion to a close, and we appreciate everyone taking part. Ladies and gentlemen, today's call ends here. Thanks to each of you for being with us. You're free to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cytek Biosciences, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Cytek Biosciences, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.